Idorsia Ltd.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Roland Wandeler
- Full Time Employees
- 487
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Hegenheimermattweg 91 Allschwil BL Switzerland 4123
- IPO Date
- Jun 16, 2017
- Website
- idorsia.com
- Similar Companies
- Business
- Idorsia Ltd. is a biopharmaceutical company focused on innovative prescription medicines for unmet medical needs, with headquarters in Allschwil, Switzerland, founded in 2017 as a spin-off of Actelion and listed on the SIX Swiss Exchange (Ticker: IDIA). The company develops, manufactures, and markets late-stage pharmaceutical therapies across multiple therapeutic areas, including cardiometabolic, central nervous system, immunology, and oncology markets, and pursues global commercialization through direct subsidiaries and strategic partnerships. Main products and services: research and development for novel small molecules and biologics; clinical development services and phase-appropriate translational research; regulatory submissions and global product approvals; manufacturing of clinical and commercial drug substances and finished dosage forms; commercial sales and marketing of approved therapies; life-cycle management, post-approval studies, and pharmacovigilance; collaboration and licensing agreements with biotechnology and pharmaceutical partners; portfolio management across specialty medicines, with a focus on patients with high unmet need; digital health and data-driven insights to support patient access and outcomes. Latest major company changes: enters strategic partnerships and licensing arrangements to expand pipeline and global reach; completes funding announcements and equity transactions to support late-stage development; advances new product candidates into pivotal trials and supports regulatory submissions in key markets; implements organizational restructurings and efficiency programs to optimize operations and cost structures; expands geographic footprint through new market approvals and commercial launches in Europe, the Americas, and Asia-Pacific. Industry and business segments: biopharmaceuticals, specialized medicines, and clinical development services; therapeutic areas include neurology, immunology, metabolic disorders, cardiovascular diseases, and oncology; revenue through product sales, collaboration and licensing revenue, and development funding; focus on rare and high-need conditions; strategic collaborations with global pharmaceutical partners. Geographic operations: operates internationally with commercial activities in Europe, North America, Asia-Pacific, and other regions; maintains manufacturing and development facilities in Switzerland and selected alliance sites; distribution through regional affiliates and distributors to multiple countries. Founding year and headquarters location: founded in 2017 as a spin-off of Actelion; headquartered in Allschwil, Switzerland. Subsidiaries/parent relationships: independent publicly traded company with subsidiaries and regional affiliates supporting research, development, and commercialization; maintains strategic partnerships and licensing agreements with third-party organizations to expand its pipeline and market access.
Company News
Idorsia Ltd (IDRSF) Q2 2026 Earnings Call Transcript
Idorsia strengthens financial position with up to CHF 250 million loan from Pharmakon
Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology
New analysis of Idorsia’s aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension
New analysis of Idorsia's aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension
Shareholders vote in favor of all proposals by the Board at Idorsia's Annual General Meeting 2026
Santhera schlägt Dr. Srishti Gupta als neues Mitglied des Verwaltungsrats
Santhera Proposes Dr. Srishti Gupta as New Member of the Board of Directors
Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year
Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders
Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development
Idorsia Ltd (IDRSF) Discusses Positive Phase II Results for Daridorexant in Pediatric Insomnia and Neurodevelopmental Disorders Transcript
Idorsia’s daridorexant delivers outstanding results in a Phase 2 study in children with insomnia disorder
Idorsia announces the nomination of three candidates for election to the Board of Directors
Idorsia announces management change
Idorsia expands QUVIVIQ's global footprint through new partnership with Pharmalink
Idorsia Ltd (IDRSF) Q4 2025 Earnings Call Transcript
Idorsia reports strong 2025 results with QUVIVIQ sales more than doubling – further sales growth ahead with multiple pipeline catalysts in 2026
Invitation to Idorsia's FY 2025 Financial Reporting webcast and conference call
Clear route to registration positions lucerastat as the potential first oral therapy for all patients with Fabry disease